Drugs / nTregs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02371434 | Feb 2015 → Nov 2017 | — | Prof. Dr. Petra Reinke | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nTregs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02371434 ↗ |
| Modality | Cell therapy | “somatic cell-based medicinal product” NCT02371434 ↗ |
| Route | Intravenous | “CD4+ CD25+ FoxP3+ nTreg products were given seven days after kidney transplantation as one intravenous dose” PMID 33087345 ↗ Oct 2020 |